The DOI matches its Crossref record; 393 of the 393 references it cites were found in a registry or an index.
Trial watch: Oncolytic viruses for cancer therapy
Open accessAbstract
Oncolytic virotherapy is emerging as a promising approach for the treatment of several neoplasms. The term "oncolytic viruses" is generally employed to indicate naturally occurring or genetically engineered attenuated viral particles that cause the demise of malignant cells while sparing their non-transformed counterparts. From a conceptual standpoint, oncolytic viruses differ from so-called "oncotropic viruses" in that only the former are able to kill cancer cells, even though both display a preferential tropism for malignant tissues. Of note, such a specificity can originate at several different steps of the viral cycle, including the entry of virions (transductional specificity) as well as their intracellular survival and replication (post-transcriptional and transcriptional specificity). During the past two decades, a large array of replication-competent and replication-incompetent oncolytic viruses has been developed and engineered to express gene products that would specifically promote the death of infected (cancer) cells. However, contrarily to long-standing beliefs, the antineoplastic activity of oncolytic viruses is not a mere consequence of the cytopathic effect, i.e., the lethal outcome of an intense, productive viral infection, but rather involves the elicitation of an antitumor immune response. In line with this notion, oncolytic viruses genetically modified to drive the local production of immunostimulatory cytokines exert more robust therapeutic effects than their non-engineered counterparts. Moreover, the efficacy of oncolytic virotherapy is significantly improved by some extent of initial immunosuppression (facilitating viral replication and spread) followed by the administration of immunostimulatory molecules (boosting antitumor immune responses). In this Trial Watch, we will discuss the results of recent clinical trials that have evaluated/are evaluating the safety and antineoplastic potential of oncolytic virotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–393 of 393
Trial Watch: Anticancer radioimmunotherapy
Vacchelli, E., Vitale, I., Tartour, É., Eggermont, A. M. M., Sautès‐Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25595 · Cited by 100
Self-citationRayet, B., López‐Guerrero, J. A., Rommelaere, J., & Dinsart, C. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8893-8903.1998 · Cited by 100
Pesonen, S. A., Diaconu, I., Cerullo, V., Escutenaire, S., Raki, M., Kangasniemi, L., Nokisalmi, P., Dotti, G., Guse, K., Laasonen, L., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26216 · Cited by 99
Trial watch: DNA vaccines for cancer therapy
Senovilla, L., Vacchelli, E., Garcia, P., Eggermont, A. M. M., Fridman, W. H., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.23803 · Cited by 99
Self-citationOncolytic Viruses as Anticancer Vaccines
Woller, N., rlevik, E. G. ⁄., Ureche, C.-I., Schumacher, A., & hnel, F. K. ⁄. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00188 · Cited by 98
Ong, H. T., Federspiel, M. J., Guo, C. M., Ooi, L. L., Russell, S. J., Peng, K.-W., & Hui, K. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.010 · Cited by 98
Cerullo, V., Diaconu, I., Romano, V. C., Hirvinen, M., Ugolini, M., Escutenaire, S., Holm, L., Kipar, A., Kanerva, A., & Hemminki, A. (2012) · Molecular Therapy · doi:10.1038/mt.2012.137 · Cited by 97
Peng, K.-W., Myers, R. M., Greenslade, A., et al. (2012) · Gene Therapy · doi:10.1038/gt.2012.31 · Cited by 96
Matsushima-Miyagi, T., Hatano, K., Nomura, M., Liu, L., Nishikawa, T., Saga, K., Shimbo, T., & Kaneda, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1595 · Cited by 96
Mésange, P., Poindessous, V., Sabbah, M., Escargueil, A. E., de Gramont, A., & Larsen, A. K. (2014) · Oncotarget · doi:10.18632/oncotarget.1671 · Cited by 95
Ganesh, S., Gonzalez-Edick, M., Gibbons, D., Roey, M. V., & Jooss, K. U. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4732 · Cited by 95
Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy
Vacchelli, E., Aranda, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.27048 · Cited by 94
Self-citationBreitbach, C. J., Moon, A., Burke, J., Hwang, T.-H., & Kirn, D. H. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_19 · Cited by 92
Barton, K. N., Paielli, D. L., Zhang, Y., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.005 · Cited by 92
Specific tumor-cell killing with adenovirus vectors containing the apoptin gene
Pietersen, A. M., van der Eb, M. M., Rademaker, H. J., van den Wollenberg, D. J. M., Rabelink, M. J. W. E., Kuppen, P. J. K., van Dierendonck, J. H., van Ormondt, H., Masman, D., van de Velde, C. J. �., et al. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300876 · Cited by 91
Hemminki, O., Parviainen, S., Juhila, J., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.2901 · Cited by 88
Kim, K. H., Dmitriev, I. P., Saddekni, S., et al. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.003 · Cited by 87
A phase I trial of intravenous infusion of ONYX-015 and enbrel in solid tumor patients
Nemunaitis, J. J., Senzer, N. N., Sarmiento, S., Zhang, Y.-A., Arzaga, R., Sands, B. E., Maples, P. B., & Tong, A. W. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701080 · Cited by 86
Optimizing DC Vaccination by Combination With Oncolytic Adenovirus Coexpressing IL-12 and GM-CSF
Zhang, S.-N., Choi, I.-K., Huang, J.-H., Yoo, J. Y., Choi, K., & Yun, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.29 · Cited by 86
Morrison, J., Briggs, S. S., Green, N. H., Fisher, K. D., Šubr, V., Ulbrich, K., Kehoe, S. T., & Seymour, L. W. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300363 · Cited by 86
Trial Watch: Toll-like receptor agonists in oncological indications
Aranda, F., Vacchelli, E., Obrist, F., Eggermont, A. M. M., Galon, J., Sautès‐Fridman, C., Cremer, I., ter Meulen, J. H., Zitvogel, L., Kroemer, G., et al. (2014) · OncoImmunology · doi:10.4161/onci.29179 · Cited by 85
Self-citationOncolytic Adenoviruses for Cancer Immunotherapy
Cerullo, V., Koski, A., Vähä-Koskela, M. J. V., & Hemminki, A. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-398342-8.00008-2 · Cited by 85
Burke, M. J., Ahern, C. H., Weigel, B. J., Poirier, J. T., Rudin, C. M., Chen, Y., Cripe, T. P., Bernhardt, M. B., & Blaney, S. M. (2014) · Pediatric Blood & Cancer · doi:10.1002/pbc.25269 · Cited by 84
Kimata, H., Imai, T., Kikumori, T., et al. (2006) · Annals of Surgical Oncology · doi:10.1245/aso.2006.08.035 · Cited by 84
Freytag, S. O., Stricker, H. J., Lü, M., Elshaikh, M. A., Aref, I., Pradhan, D. R., Levin, K. J., Kim, J. H., Peabody, J. O., Siddiqui, F., et al. (2014) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2014.02.034 · Cited by 84
Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21
Au, G. G., Lindberg, A., Barry, R. D., et al. (2005) · International Journal of Oncology · doi:10.3892/ijo.26.6.1471 · Cited by 83
Lou, W., Chen, Q., Ma, L., Liu, J., Yang, Z., Shen, J., Cui, Y., Bian, X., & Qian, C. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-012-0985-x · Cited by 82
Myeloid derived suppressor cells: Targets for therapy
Waldron, T. J., Quatromoni, J. G., Karakasheva, T. A., Singhal, S. K., & Rustgi, A. K. (2013) · OncoImmunology · doi:10.4161/onci.24117 · Cited by 81
Genetically engineered Newcastle disease virus for malignant melanoma therapy
Zamarin, D., Vigil, A., Kelly, K. J., García‐Sastre, A., & Fong, Y. (2009) · Gene Therapy · doi:10.1038/gt.2009.14 · Cited by 81
Trial Watch: Adoptive cell transfer immunotherapy
Galluzzi, L., Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Sautès‐Fridman, C., Tartour, É., Zitvogel, L., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.19549 · Cited by 81
Self-citationA model for cancer-suppressive inflammation
Haabeth, O. A. W., Bogen, B., & Corthay, A. (2012) · OncoImmunology · doi:10.4161/onci.21542 · Cited by 80
Development of PEGylated adenovirus vector with targeting ligand
Eto, Y., Yoshioka, Y., Mukai, Y., Okada, N., & Nakagawa, S. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.08.025 · Cited by 80
Wong, H. C., Jeng, E. K., & Rhode, P. R. (2013) · OncoImmunology · doi:10.4161/onci.26442 · Cited by 80
Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Vacchelli, E., Eggermont, A. M. M., Fridman, W. H., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.24238 · Cited by 79
Self-citationICOVIR-5 Shows E2F1 Addiction and Potent Antiglioma Effect In vivo
Alonso, M. M., Cascalló, M., Gomez‐Manzano, C., Jiang, H., Bekele, B. N., Pérez, A., Lang, F. F., Piao, Y., Alemany, R., & Fueyo-Margareto, J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4675 · Cited by 78
Liu, C., Russell, S. J., & Peng, K.-W. (2010) · Molecular Therapy · doi:10.1038/mt.2010.43 · Cited by 77
Kim, B., Cho, H., Chung, J., Conway, C. M., Ylaya, K., Kim, J., & Hewitt, S. M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-185 · Cited by 77
Oncolytic measles virus strains as novel anticancer agents
Msaouel, P., Opyrchal, M., Domingo‐Musibay, E., & Galanis, E. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2013.749851 · Cited by 76
Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21
Skelding, K. A., Barry, R. D., & Shafren, D. R. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9899-2 · Cited by 75
Myeloid-Derived Suppressor Cells as a Vehicle for Tumor-Specific Oncolytic Viral Therapy
Eisenstein, S. G., Coakley, B. A., Briley-Saebo, K. C., Ma, G., Chen, H.-M., Meseck, M. L., Ward, S., Divino, C. M., Woo, S. L. C., Chen, S., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1597 · Cited by 75
Labrada, L., Bodelón, G., Viñuela, J. E., & Benavente, J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.7932-7941.2002 · Cited by 75
The role of adenovirus E4orf4 protein in viral replication and cell killing
Branton, P. E., & Roopchand, D. E. (2001) · Oncogene · doi:10.1038/sj.onc.1204862 · Cited by 75
Bilbao, R., Bustos, M., Alzuguren, P., Pajares, M. J., Droździk, M., Qian, C., & Prìeto, J. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301312 · Cited by 74
Spary, L. K., Salimu, J., Webber, J. P., Clayton, A., Mason, M. D., & Tabi, Z. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955331 · Cited by 74
Suppression of Antiviral Innate Immunity by Sunitinib Enhances Oncolytic Virotherapy
Jha, B. K., Dong, B., Nguyen, C. T., Polyakova, I. V., & Silverman, R. H. (2013) · Molecular Therapy · doi:10.1038/mt.2013.112 · Cited by 73
The antitumor activity of TRAIL and IL-24 with replicating oncolytic adenovirus in colorectal cancer
Zhao, L., Dong, A., Gu, J., Liu, Z., Zhang, Y., Zhang, W., Wang, Y., He, L., Qian, C., Qian, Q., et al. (2006) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700969 · Cited by 73
Umeoka, T., Kawashima, T., Kagawa, S., Teraishi, F., Taki, M., Nishizaki, M., Kyo, S., Nagai, K., Urata, Y., Tanaka, N., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1335 · Cited by 72
Reovirus-based therapy for cancer
Kelly, K. R., Nawrocki, S. T., Mita, A. C., Coffey, M. C., Giles, F. J., & Mita, M. M. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590903002039 · Cited by 72
Oncolytic HSV-1 Virotherapy: Clinical Experience and Opportunities for Progress
Kaur, B., Chiocca, E. A., & Cripe, T. P. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958814 · Cited by 72
Common community respiratory viruses in patients with cancer
Hicks, K. L., Chemaly, R. F., & Kontoyiannis, D. P. (2003) · Cancer · doi:10.1002/cncr.11353 · Cited by 71
Carew, J. S., Espitia, C. M., Zhao, W., Kelly, K. R., Coffey, M. C., Freeman, J. W., & Nawrocki, S. T. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.259 · Cited by 70
Arulanandam, R., Batenchuk, C., Varette, O., Zakaria, C., Garcia, V., Forbes, N. E., Davis, C., Krishnan, R., Karmacharya, R., Cox, J. A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7410 · Cited by 70
Kleijn, A., Kloezeman, J. J., Treffers-Westerlaken, E., Fulci, G., Leenstra, S., Dirven, C. M. F., Debets, R., & Lamfers, M. L. M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0097495 · Cited by 70
Taube, J. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.963413 · Cited by 69
Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors
Yaacov, B., Elihaoo, E., lazar, I., Ben-Shlomo, M., Greenbaum, I., Panet, A., & Zakay-Rones, Z. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.31 · Cited by 69
The emerging role of viruses in the treatment of solid tumours
Bourke, M. G., Salwa, S., Harrington, K. J., Kucharczyk, M. J., Forde, P. F., de Kruijf, M., Soden, D. M., Tangney, M., Collins, J. K., & O’Sullivan, G. C. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.12.003 · Cited by 66
Gomes, E. M., Rodrigues, M. S., Phadke, A. P., Butcher, L. D., Starling, C. E., Chen, S., Chang, D., Hernández-Alcoceba, R., Newman, J. T., Stone, M. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1360 · Cited by 66
Trial watch: Immunostimulatory cytokines in cancer therapy
Vacchelli, E., Aranda, F., Obrist, F., Eggermont, A. M. M., Galon, J., Cremer, I., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/onci.29030 · Cited by 65
Self-citationAnti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus
Callegari, E., Elamin, B. K., D’Abundo, L., Falzoni, S., Donvito, G., Moshiri, F., Milazzo, M., Altavilla, G., Giacomelli, L., Fornari, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073964 · Cited by 65
Li, J., O’Malley, M. E., Sampath, P., Kaliński, P., Bartlett, D. L., & Thorne, S. H. (2012) · Neoplasia · doi:10.1593/neo.121272 · Cited by 64
Amit, M., & Gil, Z. (2013) · OncoImmunology · doi:10.4161/onci.27231 · Cited by 64
Berchtold, S., Lampe, J. W., Weiland, T., Smirnow, I., Schleicher, S., Handgretinger, R., Kopp, H., Reiser, J., Stubenrauch, F., Mayer, N., et al. (2013) · Journal of Virology · doi:10.1128/jvi.02106-12 · Cited by 64
Maitra, R., Seetharam, R. N., Tesfa, L., Augustine, T. A., Klampfer, L., Coffey, M. C., Mariadason, J. M., & Goel, S. (2014) · Oncotarget · doi:10.18632/oncotarget.1921 · Cited by 63
Kolb, E. A., Sampson, V. B., Stabley, D. L., Walter, A., Sol‐Church, K., Cripe, T. P., Hingorani, P., Ahern, C. H., Weigel, B. J., Zwiebel, J. A., et al. (2015) · Pediatric Blood & Cancer · doi:10.1002/pbc.25464 · Cited by 63
Cody, J. J., Markert, J. M., & Hurst, D. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092919 · Cited by 63
Trial Watch: Lenalidomide-based immunochemotherapy
Semeraro, M., Vacchelli, E., Eggermont, A. M. M., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26494 · Cited by 63
Self-citationCurrent status of gene therapy for cancer
Walther, W., & Schlag, P. M. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000004 · Cited by 63
Zhang, Q., Liang, C., Yu, Y., et al. (2009) · Molecular Genetics and Genomics · doi:10.1007/s00438-009-0475-1 · Cited by 63
Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
Liikanen, I., Koski, A., Merisalo-Soikkeli, M., Hemminki, O., Oksanen, M., Kairemo, K., Joensuu, T. K., Kanerva, A., & Hemminki, A. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.989771 · Cited by 62
Bridle, B. W., Clouthier, D., Zhang, L., Pol, J. G., Chen, L., Lichty, B. D., Bramson, J. L., & Wan, Y. (2013) · OncoImmunology · doi:10.4161/onci.26013 · Cited by 61
Goetz, C., & Gromeier, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2010.02.005 · Cited by 61
The immune checkpoint regulator PD-L1 is a specific target for naturally occurring CD4+T cells
Ahmad, S. M., Olofsson, G. H., Svane, I. M., & Andersen, M. H. (2013) · OncoImmunology · doi:10.4161/onci.23991 · Cited by 60
Wang, H., Chen, N. G., Minev, B., & Szalay, A. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-167 · Cited by 60
Markovitz, N. S., Baunoch, D., & Roizman, B. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5560-5569.1997 · Cited by 60
Kharaziha, P., Rodriguez, P. Q., Li, Q., Rundqvist, H., Björklund, A.-C., Augsten, M., Ullén, A., Egevad, L., Wiklund, P. N., Nilsson, S. F., et al. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.1 · Cited by 59
Self-citationOncolytic Poliovirus Against Malignant Glioma
Goetz, C., Dobrikova, E. Y., Shveygert, M., Dobrikov, M. I., & Gromeier, M. (2011) · Future Virology · doi:10.2217/fvl.11.76 · Cited by 59
Freytag, S. O., Barton, K. N., & Zhang, Y. (2013) · Gene Therapy · doi:10.1038/gt.2013.40 · Cited by 58
Opyrchal, M., Allen, C., Iankov, I. D., Aderca, I., Schroeder, M. A., Sarkaria, J. N., & Galanis, E. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.158 · Cited by 57
Trial Watch: Radioimmunotherapy for oncological indications
Bloy, N., Pol, J. G., Manic, G., Vitale, I., Eggermont, A. M. M., Galon, J., Tartour, É., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2014) · OncoImmunology · doi:10.4161/21624011.2014.954929 · Cited by 56
Self-citationConditional and reversible disruption of essential herpesvirus proteins
Glaß, M., Busche, A., Wagner, K., Messerle, M., & Borst, E. M. (2009) · Nature Methods · doi:10.1038/nmeth.1346 · Cited by 56
Bramante, S., Kaufmann, J. K., Veckman, V., Liikanen, I., Nettelbeck, D. M., Hemminki, O., Vassilev, L., Cerullo, V., Oksanen, M., Heiskanen, R., et al. (2015) · International Journal of Cancer · doi:10.1002/ijc.29536 · Cited by 55
Roulstone, V., Twigger, K. R., Zaidi, S. H. H., Pencavel, T. D., Kyula, J., White, C. L., McLaughlin, M., Seth, R., Karapanagiotou, E. M., Mansfield, D., et al. (2012) · Gene Therapy · doi:10.1038/gt.2012.68 · Cited by 55
Preclinical Evaluation of Oncolytic Vaccinia Virus for Therapy of Canine Soft Tissue Sarcoma
Gentschev, I., Adelfinger, M., Josupeit, R., Rudolph, S., Ehrig, K., Donat, U., Weibel, S., Chen, N. G., Yu, Y., Zhang, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037239 · Cited by 55
The host response to cancer virotherapy.
Ea, C. (2008) · PubMed · Cited by 55
Hamouda, M.-A., Belhacène, N., Puissant, A., Colosetti, P., Robert, G., Jacquel, A., Mari, B. P., Auberger, P., & Luciano, F. (2014) · Oncotarget · doi:10.18632/oncotarget.2193 · Cited by 54
Huang, T., Hlavatý, J., Ostertag, D. G., Espinoza, F. L., Martin, B., Petznek, H., Rodriguez-Aguirre, M. E., Ibañez, C. E., Kasahara, N., Günzburg, W. H., et al. (2013) · Cancer Gene Therapy · doi:10.1038/cgt.2013.51 · Cited by 53
Sampath, P., Li, J., Hou, W., Chen, H., Bartlett, D. L., & Thorne, S. H. (2012) · Molecular Therapy · doi:10.1038/mt.2012.257 · Cited by 53
Oncolytic Virus Immunotherapy for Melanoma
Dharmadhikari, N. D., Mehnert, J. M., & Kaufman, H. L. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-014-0326-0 · Cited by 53
Granot, T., Yamanashi, Y., & Meruelo, D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.215 · Cited by 53
Retargeting Vesicular Stomatitis Virus Using Measles Virus Envelope Glycoproteins
Ayala-Bretón, C., Barber, G. N., Russell, S. J., et al. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.146 · Cited by 52
Kharaziha, P., Raeve, H. D., Fristedt, C., Li, Q., Gruber, A., Johnsson, P., Kokaraki, G., Panzar, M., Laane, E., Österborg, A., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0658 · Cited by 52
Passer, B. J., Cheema, T. A., Wu, S., Wu, C.-L., Rabkin, S. D., & Martuza, R. L. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.75 · Cited by 52
Parrish, C., Scott, G. B., Migneco, G., Scott, K. J., Steele, L. P., Ilett, E. J., West, E. J., Hall, K., Selby, P. J., Buchanan, D., et al. (2015) · Leukemia · doi:10.1038/leu.2015.88 · Cited by 51
Potentiation of a recombinant oncolytic parvovirus by expression of Apoptin
Olijslagers, S., Dege, A. Y., Dinsart, C., et al. (2001) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700392 · Cited by 51
Tsuji, T., Nakamori, M., Iwahashi, M., Nakamura, M., Ojima, T., Iida, T., Katsuda, M., Hayata, K., Ino, Y., Todo, T., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27681 · Cited by 51
Tong, Y., You, L., Liu, H., Li, L., Meng, H., Qian, Q., & Qian, W. (2013) · Oncotarget · doi:10.18632/oncotarget.1018 · Cited by 51
Lee, C., Bu, L., Benedetti, A. D., Williams, B. J., Rennie, P. S., & Jia, W. W.-G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.26 · Cited by 50
Ranki, T., Joensuu, T. K., Jäger, E., Karbach, J., Wahle, C., Kairemo, K., Alanko, T., Partanen, K. P. L., Turkki, R., Linder, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.958937 · Cited by 50
Li, J., Kao, K., Li, L., Yang, T., Wu, C., Horng, Y.-M., Jia, W. W.-G., & Yang, C. (2013) · Virology Journal · doi:10.1186/1743-422x-10-241 · Cited by 50
Immune effects of 5-fluorouracil
Ghiringhelli, F., Bruchard, M., & Apétoh, L. (2013) · OncoImmunology · doi:10.4161/onci.23139 · Cited by 49
Clinical Development of Oncolytic Viruses in China
Liang, M. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958760 · Cited by 49
Patil, S., Gentschev, I., Nolte, I. J. A., Ogilvie, G., & Szalay, A. A. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-3 · Cited by 49
Nanni, P., Gatta, V., Menotti, L., Giovanni, C. D., Ianzano, M. L., Palladini, A., Grosso, V., Dall’Ora, M., Croci, S., Nicoletti, G., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003155 · Cited by 48
Recent Clinical Experience with Oncolytic Viruses
Donnelly, O., Errington‐Mais, F., Prestwich, R. J. D., Harrington, K. J., Pandha, H., Vile, R. G., & Melcher, A. A. (2012) · Current Pharmaceutical Biotechnology · doi:10.2174/138920112800958904 · Cited by 48
Choi, I., Li, Y., Oh, E., Kim, J., & Yun, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067512 · Cited by 47
An armed oncolytic measles vaccine virus eliminates human hepatoma cells independently of apoptosis
Lampe, J. W., Bossow, S., Weiland, T., Smirnow, I., Lehmann, R., Neubert, W. J., Bitzer, M., & Lauer, U. M. (2013) · Gene Therapy · doi:10.1038/gt.2013.28 · Cited by 46
Puzanov, I. J., Milhem, M. M., Andtbacka, R. H. I., Minor, D. R., Hamid, O., Ai, L., Chou, J., & Kaufman, H. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9063 · Cited by 46
Parviainen, S., Ahonen, M., Diaconu, I., Hirvinen, M., Karttunen, Å., Vähä-Koskela, M. J. V., Hemminki, A., & Cerullo, V. (2013) · Gene Therapy · doi:10.1038/gt.2013.73 · Cited by 45
Healing after death: antitumor immunity induced by oncolytic adenoviral therapy
Jiang, H., & Fueyo, J. (2014) · Oncoimmunology · doi:10.4161/21624011.2014.947872 · Cited by 44
Li, H., Peng, K.-W., & Russell, S. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.128 · Cited by 44
Raghunath, S., Samal, S. K., & Elankumaran, S. (2013) · Journal of Virology · doi:10.1128/jvi.02394-12 · Cited by 43
Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride
Skelding, K. A., Barry, R. D., & Shafren, D. R. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9614-0 · Cited by 42
Esaki, S., Goshima, F., Kimura, H., Murakami, S., & Nishiyama, Y. (2012) · International Journal of Cancer · doi:10.1002/ijc.27823 · Cited by 42
Cuevas, Y., Hernández-Alcoceba, R., Aragonés, J., Naranjo‐Suarez, S., Castellanos, M. C., Esteban, M. A., Martín-Puig, S., Landázuri, M. O., & del Peso, L. (2003) · PubMed · Cited by 42
Clements, D. R., Sterea, A. M., Kim, Y., Helson, E., Dean, C. A., Nunokawa, A., Coyle, K. M., Sharif, T., Marcato, P., Gujar, S. A., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1402132 · Cited by 41
Interferon α may be back on track to treat acute myeloid leukemia
Smits, E., Anguille, S., & Berneman, Z. N. (2013) · OncoImmunology · doi:10.4161/onci.23619 · Cited by 41
Sugio, K., Sakurai, F., Katayama, K., Tashiro, K., Matsui, H., Kawabata, K., Kawase, A., Iwaki, M., Hayakawa, T., Fujiwara, T., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2008 · Cited by 41
Carlson, L.-M., Geer, A. D., Sveinbjørnsson, B., Orrego, A., Martinsson, T., Kogner, P., & Levitskaya, J. (2013) · OncoImmunology · doi:10.4161/onci.23618 · Cited by 40
Novel immune checkpoint blocker approved for the treatment of advanced melanoma
Galluzzi, L., Kroemer, G., & Eggermont, A. M. M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.967147 · Cited by 39
Self-citationSTAT3 Activation Promotes Oncolytic HSV1 Replication in Glioma Cells
Okemoto, K., Wagner, B., Meisen, H., Haseley, A., Kaur, B., & Chiocca, E. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071932 · Cited by 38
Viral Oncolysates as Human Tumor Vaccines
Sinkovics, J. G. (1991) · International Reviews of Immunology · doi:10.3109/08830189109114875 · Cited by 38
Rommelfanger, D. M., Compte, M., Díaz, R. M., Ilett, E. J., Álvarez‐Vallina, L., Thompson, J., Kottke, T. J., Melcher, A. A., & Vile, R. G. (2012) · Molecular Therapy · doi:10.1038/mt.2012.204 · Cited by 37
Weir, G. M., Hrytsenko, О., Stanford, M. M., Berinstein, N. L., Karkada, M., Liwski, R., & Mansour, M. (2014) · OncoImmunology · doi:10.4161/21624011.2014.953407 · Cited by 37
Wei, H., Zhao, L., Hellström, I., Hellström, K. E., & Guo, Y. (2014) · OncoImmunology · doi:10.4161/onci.28248 · Cited by 37
Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer
Peng, W., Lizee, G. A., & Hwu, P. (2013) · OncoImmunology · doi:10.4161/onci.22691 · Cited by 36
Myeloid-derived suppressor cells: Cellular missiles to target tumors
Chandra, D., & Gravekamp, C. (2013) · OncoImmunology · doi:10.4161/onci.26967 · Cited by 36
Hartkopf, A. D., Bossow, S., Lampe, J. W., Zimmermann, M., Taran, F., Wallwiener, D. R., Fehm, T. N., Bitzer, M., & Lauer, U. M. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.004 · Cited by 36
Sow, H. S., & Mattarollo, S. R. (2013) · OncoImmunology · doi:10.4161/onci.27058 · Cited by 36
Shen (2010) · Oncology Reports · doi:10.3892/or_00000864 · Cited by 36
Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas
Shinoura, N., Yoshida, Y., Asai, A., et al. (2000) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700160 · Cited by 36
Oncogenic Ras inhibits IRF1 to promote viral oncolysis
Komatsu, Y., Christian, S. L., Ho, N. Y., Pongnopparat, T., Licursi, M., & Hirasawa, K. (2014) · Oncogene · doi:10.1038/onc.2014.331 · Cited by 35
Activation of the human immune system via toll‐like receptors by the oncolytic parvovirus H‐1
Sieben, M., Schäfer, P., Dinsart, C., Galle, P. R., & Moehler, M. H. (2012) · International Journal of Cancer · doi:10.1002/ijc.27938 · Cited by 35
Patil, S., Gentschev, I., Adelfinger, M., Donat, U., Heß, M., Weibel, S., Nolte, I. J. A., Frentzen, A., & Szalay, A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047472 · Cited by 34
Walter, S., Weinschenk, T., Reinhardt, C., & Singh‐Jasuja, H. (2012) · OncoImmunology · doi:10.4161/onci.22246 · Cited by 34
Cerullo, V., Vähä-Koskela, M. J. V., & Hemminki, A. (2012) · OncoImmunology · doi:10.4161/onci.20172 · Cited by 34
Passer, B. J., Cheema, T. A., Zhou, B., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0155 · Cited by 34
Targeted Oncolytic Herpes Simplex Virus Type 1 Eradicates Experimental Pancreatic Tumors
Gayral, M., Lulka, H., Hanoun, N., Biollay, C., Sèlves, J., Vignolle‐Vidoni, A., Berthommé, H., Trempat, P., Epstein, A. L., Buscail, L., et al. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.072 · Cited by 33
MicroRNA-Mediated Suppression of Oncolytic Adenovirus Replication in Human Liver
Ylösmäki, E. O., Lavilla-Alonso, S., Jäämaa, S., Vähä-Koskela, M. J. V., af Hällström, T., Hemminki, A., Arola, J. T., Mäkisalo, H., & Saksela, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054506 · Cited by 33
Current trends of anticancer immunochemotherapy
Vacchelli, E., Prada, N., Kepp, O., & Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.25396 · Cited by 32
Self-citationGriffith, T. S., Kawakita, M., Tian, J. P., Ritchey, J., Tartaglia, J., Sehgal, I., Thompson, T. C., Zhao, W., & Ratliff, T. L. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.13.998 · Cited by 32
Paglino, J. C., Andres, W., & van den Pol, A. N. (2014) · Journal of Virology · doi:10.1128/jvi.03508-13 · Cited by 31
Kottke, T. J., Chester, J. D., Ilett, E. J., Thompson, J., Díaz, R. M., Coffey, M. C., Selby, P. J., Nuovo, G. J., Pulido, J. S., Mukhopadhyay, D., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.147 · Cited by 31
Immunotherapeutic Potential of Oncolytic Vaccinia Virus
Thorne, S. H. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00155 · Cited by 31
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
Thomas, L. J., He, L.-Z., Marsh, H. C., et al. (2014) · OncoImmunology · doi:10.4161/onci.27255 · Cited by 31
Lovat, F., Ishii, H., Schiappacassi, M., Fassan, M., Barbareschi, M., Galligioni, E., Gasparini, P., Baldassarre, G., Croce, C. M., & Vecchione, A. M. (2013) · Oncotarget · doi:10.18632/oncotarget.1630 · Cited by 30
Thaçi, B., Ulasov, I. V., Ahmed, A. U., Ferguson, S. D., Han, Y. S., & Lesniak, M. S. (2012) · Gene Therapy · doi:10.1038/gt.2012.42 · Cited by 30
Ferris, R. L., Gross, N. D., Nemunaitis, J. J., Andtbacka, R. H. I., Argiris, A. E., Ohr, J. P., Vetto, J. T., Senzer, N. N., Bedell, C., Ungerleider, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.6082 · Cited by 30
Donnelly, O., Harrington, K. J., Melcher, A. A., & Pandha, H. (2013) · Journal of the Royal Society of Medicine · doi:10.1177/0141076813494196 · Cited by 29
Cheng, P.-H., Rao, X., McMasters, K. M., & Zhou, H. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057340 · Cited by 29
Yang, X., Chen, E., Jiang, H., Muszynski, K. W., Harris, R. D., Giardina, S. L., Gromeier, M., Mitra, G., & Soman, G. (2008) · Journal of Virological Methods · doi:10.1016/j.jviromet.2008.09.020 · Cited by 29
Taipale, K., Liikanen, I., Juhila, J., Turkki, R., Tähtinen, S., Kankainen, M., Vassilev, L., Ristimaki, A. P., Koski, A., Kanerva, A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.143 · Cited by 29
Malvicini, M., Alaniz, L. D., Bayo, J., García, M. G., Piccioni, F., Fiore, E. J., Atorrasagasti, C., Aquino, J. B., Matar, P., & Mazzolini, G. D. (2012) · OncoImmunology · doi:10.4161/onci.20684 · Cited by 28
Li, J., Liu, H., Li, L., Wu, H., Wang, C., YAN, Z., Wang, Y., Su, C., Jin, H., ZHOU, F., et al. (2012) · Oncology Reports · doi:10.3892/or.2012.2217 · Cited by 28
Xu, R., Yuan, Z. Y., Guan, Z. Z., et al. (2003) · PubMed · Cited by 28
Rewiring cancer cell death to enhance oncolytic viro-immunotherapy
Workenhe, S. T., & Mossman, K. L. (2013) · OncoImmunology · doi:10.4161/onci.27138 · Cited by 27
Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy
Ma, Y., Yamazaki, T., Yang, H., Kepp, O., Galluzzi, L., Zitvogel, L., Smyth, M. J., & Kroemer, G. (2013) · OncoImmunology · doi:10.4161/onci.24786 · Cited by 27
Self-citationSchipper, H., Alla, V., Meier, C., Nettelbeck, D. M., Herchenröder, O., & Pützer, B. M. (2014) · Oncotarget · doi:10.18632/oncotarget.1839 · Cited by 26
Sinkovics, J., & Horvath, J. C. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.4.765 · Cited by 26
Hasegawa, N., Abei, M., Yokoyama, K. K., Fukuda, K., Seo, E., Kawashima, R., Nakano, Y., Yamada, T., Nakade, K., Hamada, H., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28132 · Cited by 25
Kim, B.-R., Yoon, K., Byun, H., Seo, S. H., Lee, S., & Rho, S. B. (2014) · Oncotarget · doi:10.18632/oncotarget.2119 · Cited by 25
Neuroattenuation of Vesicular Stomatitis Virus through Picornaviral Internal Ribosome Entry Sites
Ammayappan, A., Nace, R. A., Peng, K.-W., & Russell, S. J. (2013) · Journal of Virology · doi:10.1128/jvi.02984-12 · Cited by 25
An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
Senovilla, L., Vitale, I., Martins, I., Kepp, O., Galluzzi, L., Zitvogel, L., Castedo, M., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.22409 · Cited by 24
Self-citationThe RIG-I/MAVS signaling pathway in cancer cell-selective apoptosis
Kaneda, Y. (2013) · OncoImmunology · doi:10.4161/onci.23566 · Cited by 23
Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma
Takehara, Y., Satoh, T., Nishizawa, A., Saeki, K., Nakamura, M., Masuzawa, M., Kaneda, Y., Katayama, I., & Yokozeki, H. (2013) · Clinical Immunology · doi:10.1016/j.clim.2013.05.019 · Cited by 23
Lin, W., Yeh, S., Yang, W., Yeh, K., Fujiwara, T., Nii, A., Chang, S., & Chen, P. (2012) · International Journal of Cancer · doi:10.1002/ijc.27770 · Cited by 23
The Janus face of cyclophosphamide
Ziccheddu, G., Proietti, E., & Moschella, F. (2013) · OncoImmunology · doi:10.4161/onci.25789 · Cited by 23
Fonteneau, J., Guillerme, J.-B., Tangy, F., & Grégoire, M. (2013) · OncoImmunology · doi:10.4161/onci.24212 · Cited by 22
Mori, I., Liu, B., Goshima, F., Ito, H., Koide, N., Yoshida, T., Yokochi, T., Kimura, Y., & Nishiyama, Y. (2005) · Microbes and Infection · doi:10.1016/j.micinf.2005.05.007 · Cited by 22
Kanerva, A., Koski, A., Liikanen, I., Oksanen, M., Joensuu, T. K., Hemminki, O., Palmgren, J., Hemminki, K., & Hemminki, A. (2014) · Molecular Therapy · doi:10.1038/mt.2014.218 · Cited by 21
Oncolytic Virotherapy Trials—Letter
Hemminki, A., Oksanen, M., & Merisalo-Soikkeli, M. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1471 · Cited by 20
MAGE-A3-specific anticancer immunotherapy in the clinical practice
Brichard, V. G., & Godechal, Q. (2013) · OncoImmunology · doi:10.4161/onci.25995 · Cited by 20
Combination of vaccine and immune checkpoint inhibitor is safe with encouraging clinical activity
Madan, R. A., Heery, C. R., & Gulley, J. L. (2012) · OncoImmunology · doi:10.4161/onci.20591 · Cited by 19
Batenchuk, C., Boeuf, F. L., Stubbert, L. J., Falls, T. J., Atkins, H. L., Bell, J. C., & Conrad, D. P. (2013) · Blood Cancer Journal · doi:10.1038/bcj.2013.23 · Cited by 19
Hirvinen, M., Heiskanen, R., Oksanen, M., Pesonen, S. K., Liikanen, I., Joensuu, T. K., Kanerva, A., Cerullo, V., & Hemminki, A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-193 · Cited by 19
Massari, I., Donnini, A., Argentati, K., Straino, S., Mangoni, A., Gaetano, C., Viticchi, C., Capogrossi, M. C., & Provinciali, M. (2002) · Experimental Gerontology · doi:10.1016/s0531-5565(02)00011-6 · Cited by 18
Dong, X., Qu, W.-Z., Ma, S., Zhu, Z., Zheng, C., He, A., Karlsson, A., Xu, K., & Zheng, X. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.09.003 · Cited by 18
Mavilio, D., & Lugli, E. (2013) · OncoImmunology · doi:10.4161/onci.26535 · Cited by 18
Li, L.-X., Zhang, Y.-L., Zhou, L., Ke, M.-L., Chen, J.-M., Fu, X., Ye, C., Wu, J.-X., Liu, R., & Huang, W. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-257 · Cited by 18
Kaufman, H. L., AMATRUDA, T. T., Nemunaitis, J. J., Chesney, J. A., Delman, K. A., S̄pitler, L. E., Collichio, F. A., Ross, M. I., Zhang, Y., Shilkrut, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.9074 · Cited by 18
Genetic delivery of an immuno RN ase by an oncolytic adenovirus enhances anticancer activity
Fernández‐Ulibarri, I., Hammer, K., Arndt, M. A. E., Kaufmann, J. K., Dorer, D. E., Engelhardt, S., Kontermann, R. E., Heß, J., Allgayer, H., Krauß, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29258 · Cited by 17
Monocytic myeloid-derived suppressor cells in advanced melanoma patients
Martens, A., Zelba, H., Garbe, C., Pawelec, G., & Weide, B. (2014) · OncoImmunology · doi:10.4161/onci.27845 · Cited by 17
Wang, H., Wei, F., Li, H., Ji, X., Li, S., & Chen, X. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1197 · Cited by 16
AMD3100 protects from UV-induced skin cancer
Byrne, S. N., & Sarchio, S. N. E. (2014) · OncoImmunology · doi:10.4161/onci.27562 · Cited by 16
Myeloid-derived suppressor cells as a Trojan horse
Pan, P., Chen, H.-M., & Chen, S. (2013) · OncoImmunology · doi:10.4161/onci.25083 · Cited by 14
Interleukin-2 treatment of tumor patients can expand regulatory T cells
Beyer, M. (2012) · OncoImmunology · doi:10.4161/onci.20639 · Cited by 13
The Role of GM-CSF in Enhancing Immunotherapy of Cancer
Thorne, S. H. (2013) · Immunotherapy · doi:10.2217/imt.13.65 · Cited by 13
New immunotherapeutic paradigms for castration-resistant prostate cancer
Galluzzi, L. (2013) · OncoImmunology · doi:10.4161/onci.26084 · Cited by 13
Self-citationTakahashi, H., Hyakusoku, H., Horii, C., Takahashi, M., Nishimura, G., Taguchi, T., Kondo, N., Sakakibara, A., Urata, Y., & Sano, D. (2013) · Head & Neck · doi:10.1002/hed.23309 · Cited by 13
Panorama From the Oncolytic Virotherapy Summit
Pol, J. G., Marguerie, M., Arulanandam, R., Bell, J. C., & Lichty, B. D. (2013) · Molecular Therapy · doi:10.1038/mt.2013.207 · Cited by 12
Viral antigen mediated NKp46 activation of NK cells results in tumor rejection via NK-DC crosstalk
Chinnery, F., KING, C. A., Elliott, T. J., Bateman, A. R., & James, E. (2012) · OncoImmunology · doi:10.4161/onci.20636 · Cited by 12
Virotherapy, gene transfer and immunostimulatory monoclonal antibodies
Quetglas, J. I., John, L. B., Kershaw, M. H., Álvarez‐Vallina, L., Melero, I., Darcy, P. K., & Smerdou, C. (2012) · OncoImmunology · doi:10.4161/onci.21679 · Cited by 9
NKG2D ligands link oncogenic RAS to innate immunity
Ho, S. S. W., & Gasser, S. (2012) · OncoImmunology · doi:10.4161/onci.22244 · Cited by 7
Synchronous apoptosis in established tumors leads to the induction of adaptive immunity
Honeychurch, J., Dive, C., & Illidge, T. (2013) · OncoImmunology · doi:10.4161/onci.24501 · Cited by 6
Cited by
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Self-citationOncolytic Viruses in Cancer Treatment: A Review
Lawler, S. E., Speranza, M.-C., Cho, C.-F., & Chiocca, E. A. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2064 · Cited by 592
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 538
Self-citationOptimizing oncolytic virotherapy in cancer treatment
Harrington, K., Freeman, D. J., Kelly, B., Harper, J., & Soria, J.-C. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 513
Metadata
- Authors
- Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., & Galluzzi, L.
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2013-06
- Volume
- 2
- Issue
- 6
- Pages
- e24612
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- OpenAlex
- W2033419482
- Cited by
- 255
- References
- 393
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.